Recent Updates in The Role of Immunotherapies in NSCLC: Translating Evidence to Clinical Practice
EP. 1: Key Decisionmaking Factors in Resectable Non–Small Cell Lung Cancer
ByBalazs Halmos, MD, MS, Montefiore Einstein Center for Cancer Care,Martin Dietrich, MD, PhD,Kristen A. Marrone, MD, Johns Hopkins Medicine ,Joshua Reuss, MD, Georgetown Lombardi Comprehensive Cancer Center Expert oncologists reflect on key factors that aid in the selection of therapy for patients diagnosed with resectable non–small cell lung cancer (NSCLC).
EP. 2: Resectable Non–Small Cell Lung Cancer: Neoadjuvant Treatment Strategies
ByBalazs Halmos, MD, MS, Montefiore Einstein Center for Cancer Care,Kristen A. Marrone, MD, Johns Hopkins Medicine ,Martin Dietrich, MD, PhD,Joshua Reuss, MD, Georgetown Lombardi Comprehensive Cancer Center Focused discussion on the selection of neoadjuvant therapy in patients with resectable NSCLC in light of recent clinical trials.
EP. 3: What is the Role of Molecular Testing in Resectable Non–Small Cell Lung Cancer?
ByBalazs Halmos, MD,Kristen A. Marrone, MD, Johns Hopkins Medicine ,Martin Dietrich, MD, PhD,Joshua Reuss, MD, Georgetown Lombardi Comprehensive Cancer Center Shared insight from key opinion leaders on the value of molecular testing in patients with resectable non–small cell lung cancer and how it can be applied.
EP. 4: Adjuvant Treatment Strategies in Resectable Non–Small Cell Lung Cancer
ByBalazs Halmos, MD, MS, Montefiore Einstein Center for Cancer Care,Kristen A. Marrone, MD, Johns Hopkins Medicine ,Martin Dietrich, MD, PhD,Joshua Reuss, MD, Georgetown Lombardi Comprehensive Cancer Center Switching their focus to the adjuvant setting of resectable NSCLC, expert panelists identify treatment options in this setting and review the clinical data behind them.
EP. 5: Considerations for Incorporating Perioperative Treatment in Resectable NSCLC
ByBalazs Halmos, MD, MS, Montefiore Einstein Center for Cancer Care,Kristen A. Marrone, MD, Johns Hopkins Medicine ,Martin Dietrich, MD, PhD,Joshua Reuss, MD, Georgetown Lombardi Comprehensive Cancer Center Before closing out their review of resectable NSCLC treatment strategies, key opinion leaders consider nuances in utilizing perioperative therapy in the current paradigm.
EP. 6: Factors in Selecting IO Therapy for Patients With Advanced NSCLC
ByBalazs Halmos, MD, MS, Montefiore Einstein Center for Cancer Care,Kristen A. Marrone, MD, Johns Hopkins Medicine ,Martin Dietrich, MD, PhD,Joshua Reuss, MD, Georgetown Lombardi Comprehensive Cancer Center Switching their focus to advanced non–small cell lung cancer, panelists identify parameters that may influence the use of immune checkpoint inhibitors in this setting.
EP. 7: Selecting Therapy for Advanced NSCLC Based on PD-L1 and NGS Testing
ByBalazs Halmos, MD, MS, Montefiore Einstein Center for Cancer Care,Kristen A. Marrone, MD, Johns Hopkins Medicine ,Martin Dietrich, MD, PhD,Joshua Reuss, MD, Georgetown Lombardi Comprehensive Cancer Center Shared insight on the value that molecular testing and PD-L1 testing, respectively, have on determining optimal therapy for patients with advanced non–small cell lung cancer.
EP. 8: Combination Chemo + IO Therapy in Advanced Non–Small Cell Lung Cancer
ByBalazs Halmos, MD, MS, Montefiore Einstein Center for Cancer Care,Kristen A. Marrone, MD, Johns Hopkins Medicine ,Martin Dietrich, MD, PhD,Joshua Reuss, MD, Georgetown Lombardi Comprehensive Cancer Center A comprehensive discussion on combination chemotherapy + immunotherapy regimens available to patients with advanced non–small cell lung cancer.
EP. 9: Role for IO Therapy in Advanced NSCLC With Concomitant KRAS and KEAP1/STK11 Mutations
ByBalazs Halmos, MD, MS, Montefiore Einstein Center for Cancer Care,Kristen A. Marrone, MD, Johns Hopkins Medicine ,Martin Dietrich, MD, PhD,Joshua Reuss, MD, Georgetown Lombardi Comprehensive Cancer Center Key opinion leaders in the field of non–small cell lung cancer management discuss the role of immunotherapy in patients with concomitant KRAS and KEAP1/STK11 mutations.
EP. 10: Advanced NSCLC: Interpreting Data From the POSEIDON Trial
ByBalazs Halmos, MD, MS, Montefiore Einstein Center for Cancer Care,Kristen A. Marrone, MD, Johns Hopkins Medicine ,Martin Dietrich, MD, PhD,Joshua Reuss, MD, Georgetown Lombardi Comprehensive Cancer Center A brief review of the POSEIDON trial, which analyzed durvalumab with or without tremelimumab in combination with chemotherapy in advanced NSCLC.
EP. 11: Optimizing the Selection of Novel Therapy for Patients With Advanced NSCLC
ByBalazs Halmos, MD, MS, Montefiore Einstein Center for Cancer Care,Kristen A. Marrone, MD, Johns Hopkins Medicine ,Martin Dietrich, MD, PhD,Joshua Reuss, MD, Georgetown Lombardi Comprehensive Cancer Center Closing out their panel on immunotherapy in non–small cell lung cancer, expert oncologists share key takeaways on the selection of novel therapy in this setting.
